Tech Company Financing Transactions

Rome Therapeutics Funding Round

Rome Therapeutics closed a $77 million Series B financing round on 9/15/2021. Investors included Section 32, Alexandria Venture Investments and Andreessen Horowitz.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

700 Main St.
Cambridge, MA 02139
USA

Phone

Undisclosed

Website

www.rometx.com

Email Address

[email protected]

Overview

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome -- vast stretches of uncharted genetic material that have long been dismissed as "junk DNA." With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Rosana Kapeller

        

Chief Scientific Officer

Dennis Zaller

        

Vice President

David Proia

        

Vice President

Donna Romero

        

VP - Bus. Development

Wenyan Miao

        

VP - Finance

Kira Nelson

        

VP - Operations

Christine Loggins

        

Browse more venture capital transactions:

Prev: 9/15/2021: CreatorIQ venture capital transaction
Next: 9/15/2021: Ambi Robotics venture capital transaction

Share this article

About Our Venture Capital Transactions Database

Our team works diligently to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary